NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development Programs

NanoViricides, Inc. has successfully closed a $6 million registered direct offering with a single healthcare institutional investor, selling 3,571,429 shares of common stock at $1.68 per share. The transaction included concurrent private placements of Series A and Series B warrants covering an equal number of shares, with exercise prices set at $1.75 and $2.00 respectively. The Series A Warrants become exercisable after six months and expire in two years, while the Series B Warrants feature a longer 5.5-year expiration period, providing the company with potential future capital infusion opportunities.

The net proceeds from this financing will be allocated toward working capital and general corporate purposes, supporting the company's ongoing clinical development programs. A.G.P./Alliance Global Partners served as the sole placement agent for the transaction, facilitating the capital raise that comes at a critical juncture for the company's research initiatives. This funding strengthens NanoViricides' financial position as it advances multiple antiviral drug candidates through the development pipeline.

NanoViricides is developing its novel nanoviricide class of drug candidates based on technology licensed from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, represents a broad-spectrum antiviral approach planned for development against multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, as well as MPOX/Smallpox infections. The company maintains a comprehensive portfolio of antiviral programs targeting various diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.

The company's platform technology stems from the TheraCour nanomedicine technology, which NanoViricides holds under exclusive perpetual licenses for multiple viral disease targets. These licenses cover Human Immunodeficiency Virus, Hepatitis B and C Viruses, Rabies, Herpes Simplex Viruses, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company anticipates pursuing additional licenses for RSV, Poxviruses, and Enteroviruses pending successful initial research outcomes.

Current development efforts are concentrated on advancing NV-387 into Phase II human clinical trials, representing a significant milestone for the company's pipeline. The additional funding provides essential resources to support these clinical advancement activities and maintain momentum across the broader research portfolio. The financing structure, combining immediate capital with potential future warrant exercises, offers both near-term operational support and longer-term financial flexibility as the company progresses its antiviral therapeutics toward clinical validation and potential regulatory submissions.